We found a bullish paper on Hims & Hers Health, Inc. (HIMS) on Substack in La Newsletter de Momentum by a Mexican investor. This article summarizes the bull paper on HIMS. HIMS Technologies, Inc. stock is trading at $17.77 as of September 27th. According to Yahoo Finance, HIMS’s trailing and forward P/E ratios were 222.12 and 42.37, respectively.
5 countries that will need doctors in 2023
Kurhan/Shutterstock.com
Hims & Hers Health, Inc. is a telemedicine company founded in 2017. The company aims to provide remotely accessible medical services by leveraging technology to connect patients with qualified medical professionals through video consultations. The company’s business model leverages a network of independent physicians and partnerships with established healthcare providers such as Labcorp and Carbon Health. This allows Hims & Hers to offer a variety of services, including counseling and health-related products such as prescription drugs and skin care products. This flexible approach allows the company to expand into new healthcare areas without the need for large investments.
Hims & Hers Health, Inc. is an interesting candidate due to its innovative approach and significant growth potential in the telemedicine industry. The company operates in areas that meet the growing demand for accessible medical services, particularly in underserved areas such as sexual health, dermatology and mental health. Hims & Hers leverages technology to provide a convenient platform to enhance your healthcare experience. One of Hims & Hers’ key features is its flexible business model, which allows it to quickly adapt to market trends and incorporate popular treatments such as GLP-1 injections for weight loss . This flexibility not only expands the company’s product offering, but also positions it to take advantage of emerging medical needs without the need for significant capital. Hims & Hers has demonstrated strong financial performance, with revenue growing at an impressive 100% annually since its inception. The company expects its first profitable quarter in the first quarter of 2024 and fiscal 2024 revenue to be between $1.37 billion and $1.4 billion. This would result in greater operating leverage potential and higher gross margins and adjusted targets of approximately 80%. Annual EBITDA margin is 10%.
Bulls see the recent stock decline as a buying opportunity as the company can adapt quickly with the help of a variety of services that meet growing consumer demand and strategic partnerships that strengthen reliability and business operations. I think so. Future growth.
story continues
Hims & Hers Health, Inc. isn’t even on our list of 31 most popular stocks among hedge funds. According to our database, 37 hedge fund portfolios held HIMS at the end of the second quarter, compared to 29 in the previous quarter. While we recognize the risks and potential of HIMS as an investment, we believe that some AI stocks are more likely to deliver higher returns and in a shorter time frame. If you’re looking for AI stocks that are more promising than HIMS but trade at less than 5x earnings, check out our report on the cheapest AI stocks.
Read next: Analysts see new $25 billion ‘opportunity’ in NVIDIA and 10 blue-chip stocks to buy in Q3 2024, according to Bank of America.
Disclosure: None. This article was originally published on Insider Monkey.
